RelB acts as a molecular switch driving chronic inflammation in glioblastoma multiforme

49Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Glioblastoma multiforme (GBM) is a primary brain tumor characterized by extensive necrosis and immunosuppressive inflammation. The mechanisms by which this inflammation develops and persists in GBM remain elusive. We identified two cytokines interleukin-1β (IL-1) and oncostatin M (OSM) that strongly negatively correlate with patient survival. We found that these cytokines activate RelB/p50 complexes by a canonical NF-κB pathway, which surprisingly drives expression of proinflammatory cytokines in GBM cells, but leads to their inhibition in non-transformed astrocytes. We discovered that one allele of the gene encoding deacetylase Sirtuin 1 (SIRT1), needed for repression of cytokine genes, is deleted in 80% of GBM tumors. Furthermore, RelB specifically interacts with a transcription factor Yin Yang 1 (YY1) in GBM cells and activates GBM-specific gene expression programs. As a result, GBM cells continuously secrete proinflammatory cytokines and factors attracting/activating glioma-associated microglia/macrophages and thus, promote a feedforward inflammatory loop.

Cite

CITATION STYLE

APA

Waters, M. R., Gupta, A. S., Mockenhaupt, K., Brown, L. S. N., Biswas, D. D., & Kordula, T. (2019). RelB acts as a molecular switch driving chronic inflammation in glioblastoma multiforme. Oncogenesis, 8(6). https://doi.org/10.1038/s41389-019-0146-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free